Compass Therapeutics (CMPX) Enterprise Value: 2023-2025
Historic Enterprise Value for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $263.5 million.
- Compass Therapeutics' Enterprise Value rose 124.86% to $263.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.5 million, marking a year-over-year increase of 78.05%. This contributed to the annual value of $72.2 million for FY2024, which is 55.58% up from last year.
- According to the latest figures from Q3 2025, Compass Therapeutics' Enterprise Value is $263.5 million, which was up 2.13% from $258.0 million recorded in Q2 2025.
- Compass Therapeutics' 5-year Enterprise Value high stood at $263.5 million for Q3 2025, and its period low was -$8.6 million during Q2 2024.
- Its 3-year average for Enterprise Value is $141.3 million, with a median of $117.2 million in 2024.
- As far as peak fluctuations go, Compass Therapeutics' Enterprise Value tumbled by 103.70% in 2024, and later surged by 3,087.06% in 2025.
- Quarterly analysis of 3 years shows Compass Therapeutics' Enterprise Value stood at $46.4 million in 2023, then soared by 55.58% to $72.2 million in 2024, then surged by 124.86% to $263.5 million in 2025.
- Its last three reported values are $263.5 million in Q3 2025, $258.0 million for Q2 2025, and $149.5 million during Q1 2025.